Literature DB >> 15905170

A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis.

Kenneth H Minor1, Christine R Schar, Grant E Blouse, Joseph D Shore, Daniel A Lawrence, Peter Schuck, Cynthia B Peterson.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) and vitronectin are cofactors involved in pathological conditions such as injury, inflammation, and cancer, during which local levels of PAI-1 are increased and the active serpin forms complexes with vitronectin. These complexes become deposited into surrounding tissue matrices, where they regulate cell adhesion and pericellular proteolysis. The mechanism for their co-localization has not been elucidated. We hypothesize that PAI-1-vitronectin complexes form in a stepwise and concentration-dependent fashion via 1:1 and 2:1 intermediates, with the 2:1 complex serving a key role in assembly of higher order complexes. To test this hypothesis, sedimentation velocity experiments in the analytical ultracentrifuge were performed to identify different PAI-1-vitronectin complexes. Analysis of sedimentation data invoked a novel multisignal method to discern the stoichiometry of the two proteins in the higher-order complexes formed (Balbo, A., Minor, K. H., Velikovsky, C. A., Mariuzza, R. A., Peterson, C. B., and Schuck, P. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 81-86). Our results demonstrate that PAI-1 and vitronectin assemble into higher order forms via a pathway that is triggered upon saturation of the two PAI-1-binding sites of vitronectin to form the 2:1 complex. This 2:1 PAI-1-vitronectin complex, with a sedimentation coefficient of 6.5 S, is the key intermediate for the assembly of higher order complexes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905170      PMCID: PMC2034521          DOI: 10.1074/jbc.M500478200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  75 in total

1.  Boundary problems in the sedimentation and electrophoresis of complex systems in rapid reversible equilibrium.

Authors:  G A GILBERT; R C JENKINS
Journal:  Nature       Date:  1956-05-05       Impact factor: 49.962

2.  Orientation of heparin-binding sites in native vitronectin. Analyses of ligand binding to the primary glycosaminoglycan-binding site indicate that putative secondary sites are not functional.

Authors:  A D Gibson; J A Lamerdin; P Zhuang; K Baburaj; E H Serpersu; C B Peterson
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

3.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

4.  Characterization of the denaturation and renaturation of human plasma vitronectin. I. Biophysical characterization of protein unfolding and multimerization.

Authors:  P Zhuang; M N Blackburn; C B Peterson
Journal:  J Biol Chem       Date:  1996-06-14       Impact factor: 5.157

5.  Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.

Authors:  D T Eitzman; R J Westrick; E G Nabel; D Ginsburg
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

Review 6.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

7.  Site-directed mutagenesis of the arginine-glycine-aspartic acid in vitronectin abolishes cell adhesion.

Authors:  R C Cherny; M A Honan; P Thiagarajan
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

8.  Activated vitronectin as a target for anticancer therapy with human antibodies.

Authors:  Haiko J Bloemendal; Hetty C de Boer; Elianne A Koop; Alice J van Dongen; Roel Goldschmeding; Wil J M Landman; Ton Logtenberg; Martijn F B G Gebbink; Emile E Voest
Journal:  Cancer Immunol Immunother       Date:  2004-06-10       Impact factor: 6.968

9.  Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

Authors:  P J Declerck; M De Mol; M C Alessi; S Baudner; E P Pâques; K T Preissner; G Müller-Berghaus; D Collen
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

10.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

Authors:  G Deng; S A Curriden; S Wang; S Rosenberg; D J Loskutoff
Journal:  J Cell Biol       Date:  1996-09       Impact factor: 10.539

View more
  11 in total

1.  Using prior knowledge in the determination of macromolecular size-distributions by analytical ultracentrifugation.

Authors:  Patrick H Brown; Andrea Balbo; Peter Schuck
Journal:  Biomacromolecules       Date:  2007-05-24       Impact factor: 6.988

2.  A new adaptive grid-size algorithm for the simulation of sedimentation velocity profiles in analytical ultracentrifugation.

Authors:  Patrick H Brown; Peter Schuck
Journal:  Comput Phys Commun       Date:  2008-01-15       Impact factor: 4.390

3.  Identification of a PAI-1-binding site within an intrinsically disordered region of vitronectin.

Authors:  Yuzhuo Chu; Joel C Bucci; Cynthia B Peterson
Journal:  Protein Sci       Date:  2019-11-20       Impact factor: 6.725

Review 4.  Evaluating the stoichiometry of macromolecular complexes using multisignal sedimentation velocity.

Authors:  Shae B Padrick; Chad A Brautigam
Journal:  Methods       Date:  2011-01-20       Impact factor: 3.608

5.  Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.

Authors:  Jan K Jensen; Lawrence C Thompson; Joel C Bucci; Poul Nissen; Peter G W Gettins; Cynthia B Peterson; Peter A Andreasen; J Preben Morth
Journal:  J Biol Chem       Date:  2011-06-21       Impact factor: 5.157

6.  Inter-alpha-trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding.

Authors:  Jennifer E Adair; Vandy Stober; Mack Sobhany; Lisheng Zhuo; John D Roberts; Masahiko Negishi; Koji Kimata; Stavros Garantziotis
Journal:  J Biol Chem       Date:  2009-04-24       Impact factor: 5.157

7.  A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity.

Authors:  Christine R Schar; Grant E Blouse; Kenneth H Minor; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2008-01-03       Impact factor: 5.157

8.  Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.

Authors:  Christine R Schar; Jan K Jensen; Anni Christensen; Grant E Blouse; Peter A Andreasen; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2008-07-24       Impact factor: 5.157

9.  Characterization of an Extensive Interface on Vitronectin for Binding to Plasminogen Activator Inhibitor-1: Adoption of Structure in an Intrinsically Disordered Region.

Authors:  Letitia O Puster; Christopher B Stanley; Vladimir N Uversky; Joseph E Curtis; Susan Krueger; Yuzhuo Chu; Cynthia B Peterson
Journal:  Biochemistry       Date:  2019-12-16       Impact factor: 3.162

10.  Determination of protein complex stoichiometry through multisignal sedimentation velocity experiments.

Authors:  Shae B Padrick; Ranjit K Deka; Jacinta L Chuang; R Max Wynn; David T Chuang; Michael V Norgard; Michael K Rosen; Chad A Brautigam
Journal:  Anal Biochem       Date:  2010-07-25       Impact factor: 3.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.